Barclays raised the firm’s price target on PTC Therapeutics (PTCT) to $45 from $43 and keeps an Equal Weight rating on the shares. After ...

Sami Corwin has given his Buy rating due to a combination of factors that favor PTC Therapeutics’ market position. The recent FDA approval of Kebilidi, a groundbreaking gene therapy for AADC ...

PTC Therapeutics (PTCT) stock on watch as company receives FDA approval for gene therapy Kebilidi for AADC deficiency. Read ...

Nov 13 (Reuters) - The U.S. Food and Drug Administration approved PTC Therapeutics' (PTCT.O), opens new tab gene ... coats in ...

Larimar Therapeutics' New Drug Could Transform Treatment For Rare Neurological Disease, Analyst Sees Over 200% Upside For Stock Oppenheimer has initiated coverage on Larimar Therapeutics ...

Tampa Bay forecasters say it’s too early to tell where the storm will go, but urged residents to keep an eye on forecasts.

BOSTON (AP) — BOSTON (AP) — PTC Inc. (PTC) on Wednesday reported fiscal fourth-quarter earnings of $126.5 million. The Boston-based company said it had net income of $1.04 per share.

For the quarter, PTC anticipates revenues to be between $598 million and $648 million. Non-GAAP earnings per share (EPS) are expected to be between $1.30 and $1.66. The Zacks Consensus Estimate ...

The biopharmaceutical company posted revenue of $196.8 million in the period, also beating Street forecasts. Five analysts surveyed by Zacks expected $173.5 million. PTC Therapeutics expects full-year ...

PTC Therapeutics Says FDA Lifts Clinical Hold On Investigational Study In Patients With Rare Weak Nerve Cell Disorder PTC Therapeutics released interim results from its Phase 2 PIVOT-HD study on ...